Chewy Inc and Chewy Pharmacy, LLC v. Covetrus, Inc.

CourtDistrict Court of Appeal of Florida
DecidedApril 3, 2024
Docket2023-2967
StatusPublished

This text of Chewy Inc and Chewy Pharmacy, LLC v. Covetrus, Inc. (Chewy Inc and Chewy Pharmacy, LLC v. Covetrus, Inc.) is published on Counsel Stack Legal Research, covering District Court of Appeal of Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Chewy Inc and Chewy Pharmacy, LLC v. Covetrus, Inc., (Fla. Ct. App. 2024).

Opinion

DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA FOURTH DISTRICT

CHEWY, INC., and CHEWY PHARMACY, LLC, Petitioners,

v.

COVETRUS, INC., Respondent.

No. 4D2023-2967

[April 3, 2024]

Petition for writ of certiorari to the Circuit Court for the Seventeenth Judicial Circuit, Broward County; Daniel A. Casey, Judge; L.T. Case No. CACE21-017496.

Jay B. Shapiro, Jenea M. Reed, and Ryan Thornton of Stearns Weaver Miller Weissler Alhadeff & Sitterson, P.A., Miami, and Matthew P. Kanny and Sylvia R. Ewald of Goodwin Procter LLP, Santa Monica, California, for petitioners.

Pravin R. Patel of Weil, Gotshal & Manges LLP, Miami, and Gregory Silbert of Weil, Gotshal & Manges LLP, New York, New York, for respondent.

CONNER, J.

The petitioner, Chewy, Inc., petitions for a writ of certiorari seeking review of an order denying its motion for protective order to prevent the deposition of its CEO. 1 The petitioner seeks to prevent the deposition of its CEO under the “apex doctrine,” which is codified in Florida Rule of Civil Procedure 1.280(h). The petitioner contends the trial court misapplied the rule in permitting the CEO’s deposition. We agree with the petitioner’s arguments and grant the petition.

1 Two petitioners, Chewy, Inc. (the “petitioner” or “Chewy”), and Chewy Pharmacy,

LLC, filed the petition in this case. However, the CEO sought to be deposed is the CEO of Chewy and holds no officer position in Chewy Pharmacy, LLC. Thus, we refer to a single petitioner in our discussion, with minimal reference to Chewy Pharmacy, LLC. Background

The petitioner and the respondent, Covetrus, Inc., are competitors in the online veterinary pharmacy business.

Prior to the suit filed below, the petitioner and a related entity, Chewy Pharmacy, LLC, sued the respondent in a separate suit in New York, asserting tortious interference and violations of business regulations in multiple states, including Florida, regarding the sale of pet medicines.

In the suit below, the petitioner sued respondent for corporate libel, defamation, and unfair competition. The suit is based on two emails which the respondent had sent to thousands of veterinarians and others in August 2021 discussing the New York litigation. Among other allegedly false statements, the complaint alleged that the emails had stated the petitioner:

(i)“is engaging in a legal maneuver to” “cut” veterinarians “out of” “the relationships [veterinarians] build with pets and their owners” and to “mute [veterinarians’] voices;” (ii) “views the vet-client-pet relationship as an impediment to sales, and they want to cut out the competition;” and (iii) is engaged in efforts to “financially damage veterinary practices.”

The petitioner alleged that these statements mischaracterize its business and the New York deceptive trade practices action.

The respondent answered the complaint and asserted an affirmative defense that its statements in the August 2021 emails were true.

The primary focus of the disputed issues in the Florida libel-defamation suit is the petitioner’s corporate view and policy position on the veterinarian-client-pet relationship (“VCPR”).

The respondent noticed the petitioner’s CEO for deposition—the first deposition which it had sought in the case below. The respondent also sought document discovery concerning the CEO’s January 2023 interview with CNBC, but the petitioner objected to that discovery.

The petitioner moved for a protective order pursuant to rule 1.280(h) because the respondent failed to exhaust other means of discovery before attempting to take the CEO’s deposition and did not demonstrate other discovery has been inadequate. Additionally, the petitioner alleged the

2 respondent would be unable to show the CEO has “unique and/or personal knowledge of the issues litigated.”

As grounds for the deposition, the respondent relied on a CNBC article published online in January 2023 entitled Chewy’s Push into Pet Telehealth Runs into Regulatory Hurdles, Skeptical Veterinarians. Pertinent portions of the article are discussed below. The article quotes and paraphrases statements directly attributed to the CEO.

The respondent argued to the trial court that the petitioner’s CEO told CNBC that the VCPR concept is an impediment to the petitioner’s business, a proposition which is central to the respondent’s truth defense. The petitioner countered that the respondent’s assertions were false, and that the respondent failed to acknowledge the article stated “Chewy said it doesn’t take a stance” on VCPR. Additionally, the petitioner’s motion asserted that because the telehealth medicine industry is “evolving,” the statements in the article eighteen months after the August 2021 emails “has, at best, questionable relevance and/or proportionality to this lawsuit.”

After conducting a hearing on the motion for protective order, the trial court denied the motion after making the following findings:

A. [The CEO] made a public statement relevant to Defendant’s truth defense. In doing so, [the CEO] directly inserted himself into this dispute. Only [the CEO] knows why he made the statement at issue and what he meant by it. Thus [the CEO] has ‘unique, personal knowledge of the issues being litigated.’ In re Amend. to Fla. Rule of Civ. Proc. 1.280, 324 So. 3d 459, 463 (Fla. 2021).

B. Other discovery to date has been inadequate to uncover the meaning and intent of [the CEO]’s statements.

C. The considerations in Florida Rule of Civil Procedure 1.280(h) support allowing [the CEO]’s deposition to go forward, at which Defendant can ask questions allowed under the rules of discovery.[ 2]

2 We note that Second District has commented in Petro Welt Trading GES.M.B.H.

v. Brinkman, 336 So. 3d 881, 883 (Fla. 2d DCA 2022), that “[t]he new rule clearly anticipates certain factual findings that the trial court should make in the first instance.” We note that the trial court order in this case made no findings orally or in writing that specifically address the burdens imposed on each side by rule

3 Additionally, the trial court granted a stay so that the petitioner could pursue certiorari review.

Certiorari Analysis

By adding subdivision (h) to Florida Rule of Civil Procedure 1.280, our supreme court formally adopted the apex doctrine, applying it to both private and government officers. In re Amend. to Fla. R. of Civ. Proc. 1.280, 324 So. 3d 459, 461 (Fla. 2021). The apex doctrine protects the operation of governmental and corporate entities by limiting the ability to depose or call as a witness the highest executives of the entity. See id. at 460–62. An erroneously entered order permitting the deposition of a CEO therefore satisfies the jurisdictional requirements for certiorari review. DecisionHR USA, Inc. v. Mills, 341 So. 3d 448, 452–57 (Fla. 2d DCA 2022) (determining that an order requiring the deposition of a CEO or government official satisfies the jurisdictional requirements for a petition for a writ of certiorari because an erroneously entered order would result in material injury for the remainder of the trial that cannot be corrected on post-judgment appeal). Thus, we proceed with determining if the trial court departed from the essential requirements of law in permitting the deposition of the petitioner’s CEO.

As discussed by the Second District,

The text of rule 1.280(h) is unambiguous, and our supreme court has provided a detailed explanation of the reasons for the rule and key aspects of its application. . . . The party resisting the deposition is burdened to persuade the court that the corporate officer is high-level and must produce an affidavit or declaration of the officer explaining that he or she “lacks unique, personal knowledge of the issues being litigated.” See Fla. R. Civ. P.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dept. of Agriculture and Consumer Services v. Broward County
810 So. 2d 1056 (District Court of Appeal of Florida, 2002)
Horne v. SCHOOL BD. OF MIAMI-DADE COUNTY
901 So. 2d 238 (District Court of Appeal of Florida, 2005)
Halderman v. Pennhurst State School & Hospital
559 F. Supp. 153 (E.D. Pennsylvania, 1982)
Miami-Dade County v. Dade County Police Benevolent Ass'n
103 So. 3d 236 (District Court of Appeal of Florida, 2012)
University of West Florida Board of Trustees v. Habegger
125 So. 3d 323 (District Court of Appeal of Florida, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Chewy Inc and Chewy Pharmacy, LLC v. Covetrus, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/chewy-inc-and-chewy-pharmacy-llc-v-covetrus-inc-fladistctapp-2024.